Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on US Healthcare Journal.
Press releases published on March 13, 2025
Ardelyx Announces the First Recipients of Derek Forfang Patient Advocate Award
GlobeNewswire
·
March 13, 2025
WALTHAM, Mass., March 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, is …
PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer
GlobeNewswire
·
March 13, 2025
Phase 1/2 trial evaluating the proprietary combination to be run under CRADA with the National Cancer Institute Second Versamune® platform candidate targets MUC1-positive solid tumors U.S. Patent #12,201,685 covering methods of using combinations of the …
Vaxart to Host Full Year 2024 Business Update and Financial Results Conference Call on March 20
GlobeNewswire
·
March 13, 2025
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the full year ended December 31, 2024 …
Montara Therapeutics Closes $20M Oversubscribed Seed Expansion, Appoints Troy Wilson as Chairman of the Board
GlobeNewswire
·
March 13, 2025
Syndicate strengthened with new investors and increased commitments from all existing investors. Total Series Seed funding reaches $28M to advance lead epilepsy program to IND, progress neurodegeneration program to development candidate (DC), and …
FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)
GlobeNewswire
·
March 13, 2025
BRISBANE, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that the Cancer …
Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update
GlobeNewswire
·
March 13, 2025
Company Achieves Key Clinical Milestone with more than 20 Patients Enrolled in Weekly Dosing Cohort of Phase 1 Trial of Decoy20 Pharmacodynamic immune activation biomarker and pharmacokinetics profiles in initial data sets appear to meet or exceed initial …
Rett Syndrome Research Trust Appoints Amy Gilliland to its Board of Trustees
GlobeNewswire
·
March 13, 2025
TRUMBULL, Conn., March 13, 2025 (GLOBE NEWSWIRE) -- The Rett Syndrome Research Trust (RSRT), the organization working to cure Rett syndrome, is pleased to announce that Amy Gilliland, President of General Dynamics Information Technology (GDIT), has joined …
Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results
GlobeNewswire
·
March 13, 2025
ASHBURN, Va., March 13, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced recent corporate …
VITAS® Healthcare Regional Medical Director Earns AAHPM Fellow Status
GlobeNewswire
·
March 13, 2025
MIAMI, March 13, 2025 (GLOBE NEWSWIRE) -- VITAS Healthcare proudly announces that Sandhya Bhalla, MD, regional medical director in California, has achieved Fellow status with the American Academy of Hospice and Palliative Medicine (AAHPM). Dr. Bhalla is …
Cellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate Update
GlobeNewswire
·
March 13, 2025
Achieves alignment with U.S. Food and Drug Administration (FDA) on regulatory path for potential accelerated approval of iopofosine I 131 as a treatment for Waldenström macroglobulinemia (WM) Evaluating timing for Phase 1 solid tumor studies; Auger- …
Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring 2025
GlobeNewswire
·
March 13, 2025
CHATHAM, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that …
Helius Medical Technologies, Inc. Announces the Establishment of a Wholly Owned Brain Computer Interface (“BCI”) Technology Private Subsidiary
GlobeNewswire
·
March 13, 2025
--Revelation Neuro, Inc. is focused on advancing development of a Non-Implantable Artificial Intelligence (“AI”) Powered BCI Technology-- --Helius’ existing IP portfolio and extensive data warehouse provides a solid foundation for AI algorithm development …
Akebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Vafseo® (vadadustat) Commercial Launch Progress Update
GlobeNewswire
·
March 13, 2025
Strong results to date of Vafseo U.S. launch; expect Vafseo Q1 2025 net product revenues of approximately $10-$11 million Cash resources and cash from operations expected to fund current operating plan for at least two years Akebia to Host Conference Call …
Vanotech Appoints Matthew Schiller to Lead Business Development
GlobeNewswire
·
March 13, 2025
ROCKAWAY, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- Vanotech Ltd, a pharmaceutical company devoted to greatly improving the lives of people living with Ophthalmic, central nervous, digestive and endocrine conditions using innovative science that results in …
ACELYRIN Adopts Limited-Duration Stockholder Rights Plan
GlobeNewswire
·
March 13, 2025
LOS ANGELES, March 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that, in response to Tang …
Aveanna Healthcare Holdings Announces Fourth Quarter and Full Year 2024 Financial Results and 2025 Outlook
GlobeNewswire
·
March 13, 2025
Fourth Quarter Revenue was $519.9 million, an 8.6% increase over the prior year period Gross margin increased 15.7% to $171.7 million compared to Q4 2023 Fourth Quarter Net income was $29.2 million compared to net loss of $25.7 million for the comparable …
RadNet, Inc. to Present at the 35th Annual Oppenheimer Healthcare MedTech & Services Conference March 17th, 2025
GlobeNewswire
·
March 13, 2025
LOS ANGELES, March 13, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced …
Verano Targets Industry’s Fastest-Growing Categories with Expansion of Savvy™ and (the) Essence™ Product Portfolios in Leading Cannabis Markets
GlobeNewswire
·
March 13, 2025
Extra Savvy, Savvy Strut, Savvy 100 Proof and (the) Essence J’s feature large-format vapes with built-in digital engagement and barrel-style pre-rolls that deliver quality, convenience and affordability CHICAGO, March 13, 2025 (GLOBE NEWSWIRE) -- Verano …
IIHS unveils 2025 TOP SAFETY PICK award winners
GlobeNewswire
·
March 13, 2025
ARLINGTON, Va., March 13, 2025 (GLOBE NEWSWIRE) -- The Insurance Institute for Highway Safety is requiring better protection for second-row occupants for the 2025 TOP SAFETY PICK and TOP SAFETY PICK+ awards, encouraging automakers to make advanced seat …
Tarsus Announces Pricing of Upsized $125.0 Million Public Offering
GlobeNewswire
·
March 13, 2025
IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”) today announced the pricing of an upsized underwritten public offering of 2,808,988 shares of its common stock at a public offering …